Recommended Starting Dose for Sumatriptan in Migraine Headaches
The recommended starting dose for sumatriptan is 50 mg orally for most patients with migraine headaches, with a maximum daily dose of 200 mg in a 24-hour period. 1, 2
Dosing Guidelines
Oral Administration
- Initial dose: 50 mg orally for most patients 1
- Alternative starting doses:
Subcutaneous Administration
- 6 mg subcutaneously for severe attacks or when significant nausea/vomiting is present 1
Dosing Considerations
Timing and Repeat Dosing
- If migraine has not resolved within 2 hours or returns after initial improvement, a second dose may be administered
- Minimum interval between doses: 2 hours 2
- Maximum daily dose: 200 mg in a 24-hour period 1, 2
Special Populations
- Hepatic impairment: Maximum single dose should not exceed 50 mg in patients with mild to moderate hepatic impairment 2
Efficacy Considerations
- The 50 mg dose provides an optimal balance of efficacy and tolerability for most patients 3
- Studies show that 50 mg provides similar headache relief to 100 mg (NNT of 3.2 vs 3.4 for headache relief at 2 hours) 4
- Patient preference studies indicate that while 35% of patients preferred 100 mg, 31% preferred 50 mg, and 25% preferred 25 mg 3
Safety and Tolerability
- Adverse events increase with higher doses:
- 25 mg: 19% incidence of adverse events
- 50 mg: 21% incidence of adverse events
- 100 mg: 30% incidence of adverse events 3
Important Precautions
- Contraindications: Sumatriptan is absolutely contraindicated in patients with:
- Uncontrolled hypertension
- Cardiovascular disease
- Basilar or hemiplegic migraine 1
- Usage limitations: Should be limited to no more than 9 days per month to prevent medication overuse headache 1
- Do not administer during migraine aura 5
- Do not use concurrently with ergotamine-containing medications 5
Clinical Pearls
- Higher doses (100 mg) may not provide additional benefit over 50 mg for many patients but carry increased risk of adverse effects 2
- The 50 mg dose likely offers the best effectiveness-to-tolerability ratio for most patients 3
- Recurrence rates are similar across all doses (33-38%), though time to recurrence may be longer with higher doses 3